Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years
Clinical trial NCT03405935 · COMPLETED
Trial details
- NCT number
- NCT03405935
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-01
- Primary completion
- 2018-11-20
- Enrollment
- 86
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.